Diagnostic accuracy of the Amsler grid and the preferential hyperacuity perimetry in the screening of patients with age-related macular degeneration: systematic review and meta-analysis
暂无分享,去创建一个
M. Thiel | L. Faes | M. Schmid | L. Bachmann | N. Bodmer | L Faes | N S Bodmer | L M Bachmann | M A Thiel | M K Schmid | Lucas M. Bachmann | Livia Faes | Michael A. Thiel | Martin Schmid
[1] J. Hillenkamp,et al. Diagnostik von Metamorphopsien bei Netzhauterkrankungen unterschiedlicher Genese , 2006, Der Ophthalmologe.
[2] P. Jüni,et al. Consequences of different diagnostic "gold standards" in test accuracy research: Carpal Tunnel Syndrome as an example. , 2005, International journal of epidemiology.
[3] Glenn J Jaffe,et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.
[4] Kang Zhang,et al. Shape discrimination test on handheld devices for patient self-test , 2010, IHI.
[5] Albert O Edwards,et al. Shape discrimination in age-related macular degeneration. , 2002, Investigative ophthalmology & visual science.
[6] Amitha Domalpally,et al. Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. , 2014, Ophthalmology.
[7] Patrick M Bossuyt,et al. We should not pool diagnostic likelihood ratios in systematic reviews , 2008, Statistics in medicine.
[8] J. R. Ferencz,et al. TOWARD EARLIER DETECTION OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION: Multicenter Evaluation of a Preferential Hyperacuity Perimeter Designed as a Home Device , 2010, Retina.
[9] N. Bressler,et al. Preferential Hyperacuity Perimeter (PreView PHP) for detecting choroidal neovascularization study. , 2005, Ophthalmology.
[10] R. Mathew,et al. Environmental Amsler test as a monitoring tool for retreatment with ranibizumab for neovascular age-related macular degeneration , 2012, Eye.
[11] A. Grzybowski,et al. M-charts as a tool for quantifying metamorphopsia in age-related macular degeneration treated with the bevacizumab injections , 2013, BMC Ophthalmology.
[12] G. E. Lang,et al. [Comparison of Preferential Hyperacuity Perimeter (PHP) test and Amsler grid test in the diagnosis of different stages of age-related macular degeneration]. , 2006, Klinische Monatsblatter fur Augenheilkunde.
[13] Glenn J Jaffe,et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. , 2013, Ophthalmology.
[14] Gary Rubin,et al. The Amsler chart: absence of evidence is not evidence of absence , 2007, British Journal of Ophthalmology.
[15] FUNCTIONAL AND MORPHOLOGIC BENEFITS IN EARLY DETECTION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION USING THE PREFERENTIAL HYPERACUITY PERIMETER , 2011, Retina.
[16] Wolfgang Fink,et al. Distinguishing wet from dry age-related macular degeneration using three-dimensional computer-automated threshold Amsler grid testing , 2011, British Journal of Ophthalmology.
[17] Lucas M. Bachmann,et al. An empirical comparison of methods for meta-analysis of diagnostic accuracy showed hierarchical models are necessary. , 2008, Journal of clinical epidemiology.
[18] T. Ciulla,et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. , 2006, Archives of ophthalmology.
[19] Susan Mallett,et al. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies , 2011, Annals of Internal Medicine.
[20] Rafael Malach,et al. Replacing the Amsler grid: a new method for monitoring patients with age-related macular degeneration. , 2003, Ophthalmology.
[21] Gerald Liew,et al. Ranibizumab for neovascular age-related macular degeneration. , 2007, The New England journal of medicine.
[22] M. Amsler,et al. L'Examen qualitatif de la fonction maculaire , 1947 .
[23] M. Elman,et al. Earliest symptoms caused by neovascular membranes in the macula. , 1986, Archives of ophthalmology.
[24] R. Guymer,et al. Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. , 2012, American journal of ophthalmology.
[25] C. Matsumoto,et al. Correlations between M-CHARTS and PHP findings and subjective perception of metamorphopsia in patients with macular diseases. , 2011, Investigative ophthalmology & visual science.
[26] R. Malach,et al. RESULTS OF A MULTICENTER CLINICAL TRIAL TO EVALUATE THE PREFERENTIAL HYPERACUITY PERIMETER FOR DETECTION OF AGE-RELATED MACULAR DEGENERATION , 2005, Retina.
[27] Peter K. Kaiser,et al. FEASIBILITY OF A NOVEL REMOTE DAILY MONITORING SYSTEM FOR AGE-RELATED MACULAR DEGENERATION USING MOBILE HANDHELD DEVICES: Results of a Pilot Study , 2013, Retina.
[28] P. Bossuyt,et al. Empirical evidence of design-related bias in studies of diagnostic tests. , 1999, JAMA.
[29] Song Zhang,et al. Handheld shape discrimination hyperacuity test on a mobile device for remote monitoring of visual function in maculopathy. , 2013, Investigative ophthalmology & visual science.
[30] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.
[31] M. Ávila,et al. Comparison of the original Amsler grid with the preferential hyperacuity perimeter for detecting choroidal neovascularization in age-related macular degeneration. , 2007, Arquivos brasileiros de oftalmologia.
[32] R. Chou,et al. Screening Older Adults for Impaired Visual Acuity: A Review of the Evidence for the U.S. Preventive Services Task Force , 2009, Annals of Internal Medicine.